Park Avenue Securities LLC Has $1.07 Million Position in argenx SE (NASDAQ:ARGX)

Park Avenue Securities LLC lifted its position in shares of argenx SE (NASDAQ:ARGX) by 6.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,804 shares of the company’s stock after buying an additional 109 shares during the period. Park Avenue Securities LLC’s holdings in argenx were worth $1,068,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. GeoWealth Management LLC boosted its position in shares of argenx by 56.3% during the fourth quarter. GeoWealth Management LLC now owns 50 shares of the company’s stock worth $31,000 after buying an additional 18 shares during the period. Whipplewood Advisors LLC acquired a new position in shares of argenx during the fourth quarter worth about $37,000. Global Retirement Partners LLC boosted its position in shares of argenx by 369.2% during the fourth quarter. Global Retirement Partners LLC now owns 61 shares of the company’s stock worth $38,000 after buying an additional 48 shares during the period. FIL Ltd acquired a new position in shares of argenx during the fourth quarter worth about $38,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of argenx during the fourth quarter worth about $38,000. 60.32% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on ARGX shares. Robert W. Baird raised argenx from a “neutral” rating to an “outperform” rating and set a $680.00 price objective for the company in a research report on Tuesday, May 13th. Deutsche Bank Aktiengesellschaft raised argenx from a “sell” rating to a “hold” rating in a research report on Wednesday, March 12th. Citigroup reissued a “buy” rating on shares of argenx in a research report on Wednesday, May 21st. Baird R W raised argenx from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 13th. Finally, Wells Fargo & Company increased their price target on argenx from $723.00 to $741.00 and gave the company an “overweight” rating in a research report on Friday, February 28th. One equities research analyst has rated the stock with a hold rating, nineteen have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $709.18.

argenx Trading Up 2.1%

Shares of NASDAQ ARGX opened at $586.76 on Friday. The firm has a market cap of $35.83 billion, a P/E ratio of -666.77 and a beta of 0.39. argenx SE has a 1-year low of $377.47 and a 1-year high of $678.21. The business’s 50 day moving average is $586.93 and its 200-day moving average is $611.85.

argenx (NASDAQ:ARGX) last announced its earnings results on Thursday, May 8th. The company reported $2.58 earnings per share for the quarter, topping analysts’ consensus estimates of $2.32 by $0.26. The company had revenue of $1.35 billion for the quarter, compared to analyst estimates of $748.34 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. Analysts forecast that argenx SE will post 3.13 EPS for the current year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.